RARE DISEASE
Sanfilippo syndrome type D
Sanfilippo syndrome type D
Sanfilippo syndrome type D
Synonyms: GNS deficiency, Glucosamine N-acetyl-6-sulfatase deficiency, MPS3D, MPSIIID, Mucopolysaccharidosis type 3D, Mucopolysaccharidosis type IIID
Synonyms: GNS deficiency, Glucosamine N-acetyl-6-sulfatase deficiency, MPS3D, MPSIIID, Mucopolysaccharidosis type 3D, Mucopolysaccharidosis type IIID
Synonyms: GNS deficiency, Glucosamine N-acetyl-6-sulfatase deficiency, MPS3D, MPSIIID, Mucopolysaccharidosis type 3D, Mucopolysaccharidosis type IIID
Drug discovery
1
drug
With orphan designation
Overview
Sanfilippo syndrome type D (mucopolysaccharidosis III D) is an ultra-rare autosomal recessive lysosomal storage disorder caused by GNS gene mutations, resulting in deficient N-acetylglucosamine-6-sulfatase activity. This enzyme defect drives heparan sulfate accumulation, causing progressive neurodegeneration with developmental regression, severe behavioral disturbances, sleep disorders, and somatic complications (hepatosplenomegaly, recurrent infections). Life expectancy typically extends into late adolescence, with respiratory failure being the primary cause of mortality [1][12][20].
Burden
Clinical: Rapid neurocognitive decline, loss of motor function, and 100% mortality by early adulthood [1][12].
Economic: U.S. lifetime cost exceeds $8 million per family, driven by intensive care needs and lost caregiver productivity [4][9].
Psychosocial: 63% of caregivers report clinically significant PTSD symptoms due to 24/7 care demands and progressive child deterioration [1][5].
Therapies
Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders, rare transplant-related disorders
Research Papers
89 drug discovery papers about Sanfilippo syndrome type D, with 2 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
89 drug discovery papers about Sanfilippo syndrome type D, with 2 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.
Mucopolysaccharidosis type III (MPS III) is a group of autosomal recessive neurodegenerative lysosomal storage disorders that causes progressive cognitive and physical impairment, predominantly in child/early adulthood. The median age of death is 17 years as there is no safe, effective treatment approved. Using faithful Drosophila and murine models of MPS III, we have characterised the MPS IIIA and MPS IIIC fly metabolome, explored the ability of oral spermidine supplementation to ameliorate clinical disease in the fly models and explored its mechanism of action in MPS IIIA mice. Spermidine is a polyamine naturally synthesised by the body. Its manufacture decreases with age. Supplementation has been reported to stimulate autophagy, reduce cell senescence and increase health/lifespan. The metabolomic evaluation confirmed that whole MPS IIIA and MPS IIIC flies exhibit a progressively deranged metabolome. Significantly up-regulated metabolites were those involved in nucleotide and purine metabolism. The most significantly down-regulated metabolites were those involved in ascorbate and aldarate metabolism. Further, spermidine levels decreased significantly in all fly genotypes with age. In short-term studies, food enriched with 5 mM spermidine improved overall fly activity and climbing ability. A 4-week study in pre-symptomatic MPS IIIA mice (3- or 6-mM spermidine, supplemented in drinking water) revealed no improvement in microgliosis or lysosomal compartment size; however, we observed a significant reduction in the astroglial response in the brain, which is believed to drive disease progression. Longer-term confirmatory studies in larger cohorts of MPS III animals are now warranted to determine whether spermidine supplementation is of benefit in preventing or slowing clinical disease in this and other childhood dementias.
2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.
Alterations in synaptic homeostasis are linked to cognitive and behavioural impairments in brain disorders. However, synaptic dysfunction in childhood dementia is poorly understood. Here, we generate human cortical circuits from induced pluripotent stem cells (iPSCs) derived from donors with Mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome, a common form of childhood-onset dementia. Action potential firing capacity and morphology of MPS IIIA patient neurons in culture are similar to those of neurons from neurotypical donors. However, long-term neural maturation reveals excitation/inhibition imbalances caused by hyperactive excitatory synapses, disrupted network dynamics, and dysregulated gene expression linked to synaptic homeostasis. This study validates in vitro human neural models to detect neurophysiological phenotypes in childhood dementias and supports drug discovery strategies that target synaptic dysfunction to improve cognition in MPS IIIA and related brain disorders.
2025-12-01 | Vascular complications and imaging-based cardiovascular risk assessment in Mucopolysaccharidoses: A systematic review.
Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterised by glycosaminoglycan (GAG) accumulation, leading to progressive multisystem disease. Cardiovascular complications, including arterial wall stiffness, and valvular dysfunction, are major causes of morbidity and mortality. Conventional cardiovascular risk tools are unreliable in MPS, and the role of vascular imaging remains underdefined. This systematic review evaluated vascular complications in paediatric and adult MPS patients, focusing on carotid intimal-media thickness (CIMT) and functional vascular parameters (e.g. carotid cross-sectional compliance (cCSC), carotid incremental elastic modulus (cIEM), carotid cross-sectional distensibility (cCSD)), to assess their utility for cardiovascular risk stratification. A systematic search of MEDLINE, EMBASE, and Cochrane Library was conducted (inception-July 2025). Eligible studies reported vascular outcomes in MPS types I, II, III, IV, VI, or VII using imaging or functional measures. Risk of bias was assessed using ROBINS-I for observational studies and RoB 2.0 for the single randomised trial. Eight studies comprising 224 patients were included. CIMT was consistently increased across subtypes, with adult values frequently observed in childhood, indicating accelerated vascular pathology. Patients demonstrated reduced arterial compliance, increased arterial stiffness, and a high prevalence of mitral and aortic valvular disease. Enzyme replacement therapy (ERT) and haematopoietic stem cell transplantation (HSCT) showed partial attenuation of vascular pathology. CIMT and vascular stiffness are sensitive markers of subclinical vasculopathy in MPS where conventional cardiovascular risk tools may remain unreliable. Standardised vascular imaging and biomarker development are needed to improve risk stratification and long-term outcomes (particularly in adults).
2026-04-29 | Short-Term Oral Spermidine Supplementation Modifies Aspects of Neurodegenerative Disease in Flies and Mice With MPS III.
Mucopolysaccharidosis type III (MPS III) is a group of autosomal recessive neurodegenerative lysosomal storage disorders that causes progressive cognitive and physical impairment, predominantly in child/early adulthood. The median age of death is 17 years as there is no safe, effective treatment approved. Using faithful Drosophila and murine models of MPS III, we have characterised the MPS IIIA and MPS IIIC fly metabolome, explored the ability of oral spermidine supplementation to ameliorate clinical disease in the fly models and explored its mechanism of action in MPS IIIA mice. Spermidine is a polyamine naturally synthesised by the body. Its manufacture decreases with age. Supplementation has been reported to stimulate autophagy, reduce cell senescence and increase health/lifespan. The metabolomic evaluation confirmed that whole MPS IIIA and MPS IIIC flies exhibit a progressively deranged metabolome. Significantly up-regulated metabolites were those involved in nucleotide and purine metabolism. The most significantly down-regulated metabolites were those involved in ascorbate and aldarate metabolism. Further, spermidine levels decreased significantly in all fly genotypes with age. In short-term studies, food enriched with 5 mM spermidine improved overall fly activity and climbing ability. A 4-week study in pre-symptomatic MPS IIIA mice (3- or 6-mM spermidine, supplemented in drinking water) revealed no improvement in microgliosis or lysosomal compartment size; however, we observed a significant reduction in the astroglial response in the brain, which is believed to drive disease progression. Longer-term confirmatory studies in larger cohorts of MPS III animals are now warranted to determine whether spermidine supplementation is of benefit in preventing or slowing clinical disease in this and other childhood dementias.
2026-04-08 | Modelling synaptic dysfunction in childhood dementia using human iPSC-derived cortical networks.
Alterations in synaptic homeostasis are linked to cognitive and behavioural impairments in brain disorders. However, synaptic dysfunction in childhood dementia is poorly understood. Here, we generate human cortical circuits from induced pluripotent stem cells (iPSCs) derived from donors with Mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome, a common form of childhood-onset dementia. Action potential firing capacity and morphology of MPS IIIA patient neurons in culture are similar to those of neurons from neurotypical donors. However, long-term neural maturation reveals excitation/inhibition imbalances caused by hyperactive excitatory synapses, disrupted network dynamics, and dysregulated gene expression linked to synaptic homeostasis. This study validates in vitro human neural models to detect neurophysiological phenotypes in childhood dementias and supports drug discovery strategies that target synaptic dysfunction to improve cognition in MPS IIIA and related brain disorders.
2025-12-01 | Vascular complications and imaging-based cardiovascular risk assessment in Mucopolysaccharidoses: A systematic review.
Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterised by glycosaminoglycan (GAG) accumulation, leading to progressive multisystem disease. Cardiovascular complications, including arterial wall stiffness, and valvular dysfunction, are major causes of morbidity and mortality. Conventional cardiovascular risk tools are unreliable in MPS, and the role of vascular imaging remains underdefined. This systematic review evaluated vascular complications in paediatric and adult MPS patients, focusing on carotid intimal-media thickness (CIMT) and functional vascular parameters (e.g. carotid cross-sectional compliance (cCSC), carotid incremental elastic modulus (cIEM), carotid cross-sectional distensibility (cCSD)), to assess their utility for cardiovascular risk stratification. A systematic search of MEDLINE, EMBASE, and Cochrane Library was conducted (inception-July 2025). Eligible studies reported vascular outcomes in MPS types I, II, III, IV, VI, or VII using imaging or functional measures. Risk of bias was assessed using ROBINS-I for observational studies and RoB 2.0 for the single randomised trial. Eight studies comprising 224 patients were included. CIMT was consistently increased across subtypes, with adult values frequently observed in childhood, indicating accelerated vascular pathology. Patients demonstrated reduced arterial compliance, increased arterial stiffness, and a high prevalence of mitral and aortic valvular disease. Enzyme replacement therapy (ERT) and haematopoietic stem cell transplantation (HSCT) showed partial attenuation of vascular pathology. CIMT and vascular stiffness are sensitive markers of subclinical vasculopathy in MPS where conventional cardiovascular risk tools may remain unreliable. Standardised vascular imaging and biomarker development are needed to improve risk stratification and long-term outcomes (particularly in adults).
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Sanfilippo syndrome type D.
1 orphan drug designation for Sanfilippo syndrome type D.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS) | proteins | FDA | 2024-01-16 | — | Phoenix Nest Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.